Preventive role of Dietary Phytochemical Lupeol in Preclinical Ulcerative Colitis Models

Abstract

Background: The primary cause of intestinal and colon inflammation is inflammatory bowel disease (IBD).Preclinical ulcerative colitis is poorly definedin this article we providea scientific validation in preclinical systemic inflammation in ulcerative colitis by the means of phytochemical lupeol as a source of triterpenoid rich food. Aim: The aim of the present study was to evaluate the bioactive phytochemical, lupeol for the management of IBD through two different experimental models. Method: The intestinal anti-inflammatory models for rat colitis were performed by using TNBS and DSS to access the use of lupeol (25μg/ml and 50μg/ml) in ulcerative colitis. Change in body weight, stool consistency, colon weight/length and histological examination of colon were performed. Results: Lupeol showed significant anti-inflammatory impact in the colon at both the doses in TNBS and DSS models. The results of lupeol showed marked evidence both by histologically and also by the tissue recovery seen in various parameters like, Change in body weight, stool consistency and colon weight/length. Conclusion: The findings of this study provide the full proof rationale for additional research using lupeol in the successful management of ulcerative colitis.